Surface Oncology, Inc. (SURF): Price and Financial Metrics


Surface Oncology, Inc. (SURF): $0.92

-0.02 (-2.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SURF POWR Grades

  • SURF scores best on the Sentiment dimension, with a Sentiment rank ahead of 88.02% of US stocks.
  • SURF's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • SURF's current lowest rank is in the Momentum metric (where it is better than 4.51% of US stocks).

SURF Stock Summary

  • With a one year PEG ratio of 0.18, SURFACE ONCOLOGY INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 2.51% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, SURFACE ONCOLOGY INC is reporting a growth rate of -472.29%; that's higher than only 3.61% of US stocks.
  • Revenue growth over the past 12 months for SURFACE ONCOLOGY INC comes in at -66.53%, a number that bests just 2.63% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to SURF, based on their financial statements, market capitalization, and price volatility, are GSIT, SGTX, IKNA, INO, and SQZ.
  • SURF's SEC filings can be seen here. And to visit SURFACE ONCOLOGY INC's official web site, go to www.surfaceoncology.com.

SURF Valuation Summary

  • SURF's price/sales ratio is 2; this is 58.33% lower than that of the median Healthcare stock.
  • SURF's price/earnings ratio has moved up 6.9 over the prior 56 months.

Below are key valuation metrics over time for SURF.

Stock Date P/S P/B P/E EV/EBIT
SURF 2022-11-25 2.0 0.5 -0.9 -0.8
SURF 2022-11-23 2.0 0.5 -0.9 -0.8
SURF 2022-11-22 2.0 0.5 -0.9 -0.8
SURF 2022-11-21 2.0 0.5 -0.9 -0.8
SURF 2022-11-18 2.0 0.5 -0.9 -0.8
SURF 2022-11-17 2.1 0.6 -1.0 -0.9

SURF's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SURF has a Quality Grade of B, ranking ahead of 78.21% of graded US stocks.
  • SURF's asset turnover comes in at 0.436 -- ranking 105th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows SURF's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.436 1 0.130
2021-06-30 0.459 1 0.186
2021-03-31 0.488 1 0.247
2020-12-31 0.779 1 0.702
2020-09-30 0.278 1 -0.261
2020-06-30 0.283 1 -0.255

SURF Price Target

For more insight on analysts targets of SURF, see our SURF price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.60 Average Broker Recommendation 1.25 (Strong Buy)

SURF Stock Price Chart Interactive Chart >

Price chart for SURF

SURF Price/Volume Stats

Current price $0.92 52-week high $5.98
Prev. close $0.94 52-week low $0.90
Day low $0.90 Volume 269,209
Day high $0.97 Avg. volume 619,736
50-day MA $1.08 Dividend yield N/A
200-day MA $1.87 Market Cap 55.70M

Surface Oncology, Inc. (SURF) Company Bio


Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company’s lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.


SURF Latest News Stream


Event/Time News Detail
Loading, please wait...

SURF Latest Social Stream


Loading social stream, please wait...

View Full SURF Social Stream

Latest SURF News From Around the Web

Below are the latest news stories about SURFACE ONCOLOGY INC that investors may wish to consider to help them evaluate SURF as an investment opportunity.

Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting

Data further support SRF388 and SRF114 clinical development programsCAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of two posters at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston. The posters feature new non-clinical data for both SRF388 and for SRF114 and will be presented

Yahoo | November 7, 2022

Analysts Just Made A Significant Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts

Celebrations may be in order for Surface Oncology, Inc. ( NASDAQ:SURF ) shareholders, with the analysts delivering a...

Yahoo | November 7, 2022

H.C. Wainwright Keeps Their Buy Rating on Surface Oncology (SURF)

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Surface Oncology (SURF - Research Report) today and set a price target of $6.00. The company's shares closed yesterday at $1.29.Ramakanth covers the Healthcare sector, focusing on stocks such as MiMedx Group, Rewalk Robotics, and X4 Pharmaceuticals. According to TipRanks, Ramakanth has an average return of -12.7% and a 29.16% success rate on recommended stocks. Surface Oncology has an analyst consensus of Strong Buy, with a price target consensus of $6.75, which is a 423.26% upside from current levels. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $3.00 price target.

Jason Carr on TipRanks | November 3, 2022

Analysts’ Top Healthcare Picks: LivaNova (LIVN), Surface Oncology (SURF)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on LivaNova (LIVN – Research Report) and Surface Oncology (SURF – Research Report) with bullish sentiments. LivaNova (LIVN) Needham analyst Michael Matson reiterated a Buy rating on LivaNova today and set a price target of $77.00. The company's shares closed last Wednesday at $47.55, close to its 52-week low of $41.82. According to TipRanks.

Howard Kim on TipRanks | November 2, 2022

Surface Oncology Discontinues Work On One Phase 2 Cancer Program, Lays Off 20% Workforce

Surface Oncology Inc (NASDAQ: SURF) observed confirmed partial responses from SRF388 monotherapy data in non-small cell lung cancer (NSCLC) patients. The partial responses were observed in patients treated at or above the recommended Phase 2 dose (22% ORR (2/9)), which includes 100% (2/2) of patients with squamous NSCLC. Additionally, a patient with adenocarcinoma has experienced durable disease stabilization, ongoing for more than 56 weeks. Surface has initiated a single-arm Phase 2 study evalu

Yahoo | November 2, 2022

Read More 'SURF' Stories Here

SURF Price Returns

1-mo -25.81%
3-mo -29.23%
6-mo -52.33%
1-year -84.06%
3-year -56.19%
5-year N/A
YTD -80.75%
2021 -48.27%
2020 391.49%
2019 -55.66%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0216 seconds.